Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Market Closed 03-06 16:00:00 EST

1.06

+0.01

+0.95%

盘后1.08

+0.02+1.89%

18:57 EST

High1.12	Low1.02	Vol893.92K
Open1.05	D1 Closing1.05	Amplitude8.60%
Mkt Cap114.48M	Tradable Cap112.36M	Total Shares108.00M
T/O956.21K	T/O Rate0.84%	Tradable Shares106.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":1.06,"timestamp":1772830800000,"preClose":1.05,"halted":0,"volume":893916,"hourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.06,"latestTime":"18:57 EST","volume":1485,"amount":1552.26,"timestamp":1772841439806,"change":0.02,"changeRate":0.018868,"amplitude":0.037736},"delay":0,"changeRate":0.009523809523809532,"floatShares":106000000,"shares":108000000,"eps":-0.285545,"marketStatus":"Market Closed","change":0.01,"latestTime":"03-06 16:00:00 EST","open":1.05,"high":1.115,"low":1.0247,"amount":956212.1121239999,"amplitude":0.086,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.285545,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773043200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":1.05,"preHourTrading":{"tag":"盘前","latestPrice":1.0498,"preClose":1.05,"latestTime":"09:20 EST","volume":3462,"amount":3631.7290506,"timestamp":1772806810968,"change":-0.0002,"changeRate":-0.00019,"amplitude":0.019048},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.06,"latestTime":"18:57 EST","volume":1485,"amount":1552.26,"timestamp":1772841439806,"change":0.02,"changeRate":0.018868,"amplitude":0.037736},"volumeRatio":0.7864241746871602},"requestUrl":"/m/hq/s/ONCY/tweets","defaultTab":"tweets","newsList":[{"id":"2616810326","title":"Oncolytics Biotech Inc  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2616810326","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616810326?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:15","pubTimestamp":1772547308,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc  expected to post a loss of9cents a share - Earnings Preview Oncolytics Biotech Inc ONCY.OQ ONCY.O is expected to  show no change in quarterly revenue when it reports  results o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL8N3ZR1UQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2616358796","title":"Oncolytics Biotech Inc - Initiates Phase 2 Study for Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616358796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616358796?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:17","pubTimestamp":1772461037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2616651358","title":"Oncolytics Biotech launches REO 033 Phase 2 metastatic colorectal cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616651358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616651358?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:01","pubTimestamp":1772460081,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. has initiated a Phase 2 randomized study  in second-line RAS-mutated, microsatellite-stable metastatic colorectal cancer. The trial will compare a control regimen of bevacizumab plus FOLFIRI versus an experimental regimen of pelareorep plus bevacizumab and FOLFIRI, with objective response rate as the primary endpoint and progression-free survival, overall survival, safety, and biomarker analyses as additional endpoints. The company said preliminary results are expected by the end of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLdxDyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","NDAQ","ONCY","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","BK4139","BK4112"],"gpt_icon":0},{"id":"2614316700","title":"Lake Street Sticks to Their Buy Rating for Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614316700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614316700?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:05","pubTimestamp":1772035546,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Oncolytics Biotech today and set a price target of $7.00. According to TipRanks, Messer ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-their-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-their-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","ONCY"],"gpt_icon":0},{"id":"2614038755","title":"Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2614038755","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614038755?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:28","pubTimestamp":1772026124,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech (ONCY) has attracted fresh attention after a recent move in its share price, with the stock closing at US$1.13 and showing mixed return patterns across the past year and over multiple years.\nSee our latest analysis for Oncolytics Biotech.\nThe recent 6.6% 1 day share price return and 10.8% 7 day share price return suggest short term momentum is building around Oncolytics Biotech, even as the 58.3% 1 year total shareholder return contrasts with weaker 3 and 5 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oncy/oncolytics-biotech/news/oncolytics-biotech-oncy-valuation-check-after-recent-share-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oncy/oncolytics-biotech/news/oncolytics-biotech-oncy-valuation-check-after-recent-share-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4588","BK4139","LABU","BK4585","ONCY"],"gpt_icon":0},{"id":"2613178457","title":"Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2613178457","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613178457?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941677,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design. Oncolytics Biotech Inc. plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer  and metastatic colorectal cancer . The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3Tj1fl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","ONCY","IE00B3QW5Z07.USD","BK4585","SG9999014013.SGD","LU2095319765.USD","BK4588","BK4139","NDAQ"],"gpt_icon":0},{"id":"2611159069","title":"Oncolytics Biotech Director Deborah Margaret Brown Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611159069","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611159069?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984072,"startTime":"0","endTime":"0","summary":"Deborah Margaret Brown, Director at Oncolytics Biotech Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7lZcpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2611041159","title":"Director Wayne Pisano Acquires Common Shares of Oncolytics Biotech Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2611041159","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611041159?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984070,"startTime":"0","endTime":"0","summary":"Wayne Pisano, Director, reported the acquisition of common shares of Oncolytics Biotech Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7sXcK2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2611590271","title":"Allison Hagerman, VP Product Development, Reports Acquisition of Oncolytics Biotech Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611590271","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611590271?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984067,"startTime":"0","endTime":"0","summary":"Allison Hagerman, Vice President of Product Development, reported the acquisition of common shares of Oncolytics Biotech Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL9g7HNt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2611159082","title":"Director Bernd R. Seizinger Reports Acquisition of Oncolytics Biotech Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611159082","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611159082?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984064,"startTime":"0","endTime":"0","summary":"Bernd R. Seizinger, Director at Oncolytics Biotech Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL9VgTwq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Bernd R. Seizinger Reports Acquisition of Oncolytics Biotech Inc. Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2609971365","title":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609971365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609971365?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:30","pubTimestamp":1770391848,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM – Research Report), Oncolytics Biotech ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-oncolytics-biotech-oncy-and-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-oncolytics-biotech-oncy-and-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","XLV","LU0053671581.USD","INSM","IMNN","LU0109394709.USD","LU0320765992.SGD","ONCY","LU0889565916.HKD","BK4585","LU0029874061.USD","BK4588","BK4581","BK4139","HCSG","LU0128526141.USD","LABU"],"gpt_icon":0},{"id":"2609309931","title":"Oncolytics Biotech Appoints John McAdory and Yujun Wu to Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309931","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609309931?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:26","pubTimestamp":1770301579,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. has announced two new leadership appointments: John McAdory joins as Executive Vice President of Strategy and Operations, and Yujun Wu becomes Vice President, Head of Biostatistics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL8gW0pc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","ONCY","BK4588","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2608367402","title":"Oncolytics receives FDA Fast Track Designation for pelareorep","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367402","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367402?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:55","pubTimestamp":1770213327,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced that the U.S. Food and Drug Administration has granted Fast Track Designation to pelareorep in combination with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-receives-fda-fast-track-designation-for-pelareorep-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-receives-fda-fast-track-designation-for-pelareorep-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588","BK4139","ONCY"],"gpt_icon":0},{"id":"2608367325","title":"FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367325","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367325?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:50","pubTimestamp":1770213014,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. announced that the U.S. Food and Drug Administration  has granted Fast Track Designation to pelareorep in combination with bevacizumab  and FOLFIRI for the treatment of patients with KRAS-mutant, microsatellite-stable metastatic colorectal cancer in the second-line setting. The company plans to initiate a controlled clinical study comparing standard-of-care therapy alone versus standard-of-care plus pelareorep, with interim data expected by the end of 2026. This designation is intended to facilitate the development and expedite the review of therapies that address unmet medical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL1H35ch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","LU2210149790.SGD","SG9999014021.USD","BK4585","ONCY","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2608367872","title":"Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L Kras-Mutant Mss Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367872?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:50","pubTimestamp":1770213000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUAC63QT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"gpt_icon":0},{"id":"2608367322","title":"Oncolytics Biotech Inc - to Launch Controlled Study in Second-Line Kras-Mutant Mss Mcrc With Interim Data Expected by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608367322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608367322?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:50","pubTimestamp":1770213000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUAC63QT8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2605481145","title":"Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605481145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605481145?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:40","pubTimestamp":1769013615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), Artiva ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-artiva-biotherapeutics-inc-artv-and-oncolytics-biotech-oncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","TRVI","HCSG","LABU","ARTV","LU0029874061.USD","LU0128526141.USD","BK4007","BK4588","XBI","BK4137","BK4139","XLV","ONCY"],"gpt_icon":0},{"id":"2605419641","title":"Oncolytics Biotech Director Bernd R. Seizinger Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605419641","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605419641?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:31","pubTimestamp":1768944674,"startTime":"0","endTime":"0","summary":"Bernd R. Seizinger, Director at Oncolytics Biotech Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL50HRgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Oncolytics Biotech Director Bernd R. Seizinger Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"gpt_icon":0},{"id":"2603935685","title":"Oncolytics Biotech Inc. Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2603935685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603935685?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:01","pubTimestamp":1768510885,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. held a Special Meeting of Shareholders on January 15, 2026. Shareholders approved a proposal to continue the company from the Province of Alberta to the Province of British Columbia in Canada, and another proposal to continue the company from the Province of British Columbia to the State of Nevada in the United States. In addition, shareholders approved the implementation of the Oncolytics Biotech Inc. 2026 Incentive Award Plan, conditional upon completion of the continuance and domestication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire  on January 15, 2026, and is solely responsible for the information c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLxhHpB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD","SG9999014013.SGD","ONCY","BK4585","BK4588","LU2210149790.SGD","NDAQ","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2603611437","title":"Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Yujun Wu as Head of Biostatistics","url":"https://stock-news.laohu8.com/highlight/detail?id=2603611437","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603611437?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:01","pubTimestamp":1768399317,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. McAdory will oversee clinical development execution and operational strategy, while Wu will lead biostatistics and statistical strategy for the company’s clinical programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire  on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL2k4DFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","LU2095319765.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","SG9999014039.USD","IE00B64PRP62.GBP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0619},{"period":"1month","weight":0.1778},{"period":"3month","weight":0.0684},{"period":"6month","weight":0},{"period":"1year","weight":0.4422},{"period":"ytd","weight":0.2128}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0201},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0388},{"period":"1year","weight":0.174},{"period":"ytd","weight":-0.014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.100248},{"month":4,"riseRate":0.714286,"avgChangeRate":0.022868},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.009291},{"month":6,"riseRate":0.285714,"avgChangeRate":0.190573},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction